FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2109611268> ?p ?o ?g. }

• W2109611268 endingPage "1036" @default.
• W2109611268 startingPage "1025" @default.
• W2109611268 abstract "Background Safe and effective treatments are urgently needed for patients with relapsed or refractory acute myeloid leukaemia. We investigated the efficacy and safety of vosaroxin, a first-in-class anticancer quinolone derivative, plus cytarabine in patients with relapsed or refractory acute myeloid leukaemia. Methods This phase 3, double-blind, placebo-controlled trial was undertaken at 101 international sites. Eligible patients with acute myeloid leukaemia were aged 18 years of age or older and had refractory disease or were in first relapse after one or two cycles of previous induction chemotherapy, including at least one cycle of anthracycline (or anthracenedione) plus cytarabine. Patients were randomly assigned 1:1 to vosaroxin (90 mg/m2 intravenously on days 1 and 4 in a first cycle; 70 mg/m2 in subsequent cycles) plus cytarabine (1 g/m2 intravenously on days 1–5) or placebo plus cytarabine through a central interactive voice system with a permuted block procedure stratified by disease status, age, and geographical location. All participants were masked to treatment assignment. The primary efficacy endpoint was overall survival and the primary safety endpoint was 30-day and 60-day all-cause mortality. Efficacy analyses were done by intention to treat; safety analyses included all treated patients. This study is registered with ClinicalTrials.gov, number NCT01191801. Findings Between Dec 17, 2010, and Sept 25, 2013, 711 patients were randomly assigned to vosaroxin plus cytarabine (n=356) or placebo plus cytarabine (n=355). At the final analysis, median overall survival was 7·5 months (95% CI 6·4–8·5) in the vosaroxin plus cytarabine group and 6·1 months (5·2–7·1) in the placebo plus cytarabine group (hazard ratio 0·87, 95% CI 0·73–1·02; unstratified log-rank p=0·061; stratified p=0·024). A higher proportion of patients achieved complete remission in the vosaroxin plus cytarabine group than in the placebo plus cytarabine group (107 [30%] of 356 patients vs 58 [16%] of 355 patients, p<0·0001). Early mortality was similar between treatment groups (30-day: 28 [8%] of 355 patients in the vosaroxin plus cytarabine group vs 23 [7%] of 350 in the placebo plus cytarabine group; 60-day: 70 [20%] vs 68 [19%]). Treatment-related deaths occurred at any time in 20 (6%) of 355 patients given vosaroxin plus cytarabine and in eight (2%) of 350 patients given placebo plus cytarabine. Treatment-related serious adverse events occurred in 116 (33%) and 58 (17%) patients in each group, respectively. Grade 3 or worse adverse events that were more frequent in the vosaroxin plus cytarabine group than in the placebo plus cytarabine group included febrile neutropenia (167 [47%] vs 117 [33%]), neutropenia (66 [19%] vs 49 [14%]), stomatitis (54 [15%] vs 10 [3%]), hypokalaemia (52 [15%] vs 21 [6%]), bacteraemia (43 [12%] vs 16 [5%]), sepsis (42 [12%] vs 18 [5%]), and pneumonia (39 [11%] vs 26 [7%]). Interpretation Although there was no significant difference in the primary endpoint between groups, the prespecified secondary analysis stratified by randomisation factors suggests that the addition of vosaroxin to cytarabine might be of clinical benefit to some patients with relapsed or refractory acute myeloid leukaemia. Funding Sunesis Pharmaceuticals." @default.
• W2109611268 created "2016-06-24" @default.
• W2109611268 creator A5000750846 @default.
• W2109611268 creator A5003572390 @default.
• W2109611268 creator A5005591514 @default.
• W2109611268 creator A5010990164 @default.
• W2109611268 creator A5012863731 @default.
• W2109611268 creator A5015140142 @default.
• W2109611268 creator A5015493242 @default.
• W2109611268 creator A5016794322 @default.
• W2109611268 creator A5027866282 @default.
• W2109611268 creator A5028145932 @default.
• W2109611268 creator A5030342776 @default.
• W2109611268 creator A5037133740 @default.
• W2109611268 creator A5037299848 @default.
• W2109611268 creator A5038267754 @default.
• W2109611268 creator A5041443589 @default.
• W2109611268 creator A5041745367 @default.
• W2109611268 creator A5043240739 @default.
• W2109611268 creator A5045087884 @default.
• W2109611268 creator A5047713667 @default.
• W2109611268 creator A5049385583 @default.
• W2109611268 creator A5050556099 @default.
• W2109611268 creator A5050940843 @default.
• W2109611268 creator A5053578678 @default.
• W2109611268 creator A5053724616 @default.
• W2109611268 creator A5060015628 @default.
• W2109611268 creator A5060175597 @default.
• W2109611268 creator A5061334352 @default.
• W2109611268 creator A5065511282 @default.
• W2109611268 creator A5069133845 @default.
• W2109611268 creator A5072721892 @default.
• W2109611268 creator A5075883846 @default.
• W2109611268 creator A5077099095 @default.
• W2109611268 creator A5078887304 @default.
• W2109611268 creator A5085056360 @default.
• W2109611268 creator A5086668079 @default.
• W2109611268 creator A5090435894 @default.
• W2109611268 date "2015-09-01" @default.
• W2109611268 modified "2023-09-30" @default.
• W2109611268 title "Vosaroxin plus cytarabine versus placebo plus cytarabine in patients with first relapsed or refractory acute myeloid leukaemia (VALOR): a randomised, controlled, double-blind, multinational, phase 3 study" @default.
• W2109611268 cites W1569756545 @default.
• W2109611268 cites W1984229644 @default.
• W2109611268 cites W1986129214 @default.
• W2109611268 cites W1990766453 @default.
• W2109611268 cites W1996264890 @default.
• W2109611268 cites W2002689332 @default.
• W2109611268 cites W2010655738 @default.
• W2109611268 cites W2012891007 @default.
• W2109611268 cites W2016883830 @default.
• W2109611268 cites W2048312112 @default.
• W2109611268 cites W2058188142 @default.
• W2109611268 cites W2065559112 @default.
• W2109611268 cites W2069607843 @default.
• W2109611268 cites W2075320923 @default.
• W2109611268 cites W2088238660 @default.
• W2109611268 cites W2088655914 @default.
• W2109611268 cites W2097192169 @default.
• W2109611268 cites W2104590411 @default.
• W2109611268 cites W2106688219 @default.
• W2109611268 cites W2106742754 @default.
• W2109611268 cites W2107398329 @default.
• W2109611268 cites W2115731038 @default.
• W2109611268 cites W2116858301 @default.
• W2109611268 cites W2128036895 @default.
• W2109611268 cites W2133650635 @default.
• W2109611268 cites W2135763833 @default.
• W2109611268 cites W2146440927 @default.
• W2109611268 cites W2150480709 @default.
• W2109611268 cites W2159507916 @default.
• W2109611268 cites W2159746057 @default.
• W2109611268 cites W2163123363 @default.
• W2109611268 cites W2184190880 @default.
• W2109611268 cites W4376595466 @default.
• W2109611268 doi "https://doi.org/10.1016/s1470-2045(15)00201-6" @default.
• W2109611268 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4822512" @default.
• W2109611268 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26234174" @default.
• W2109611268 hasPublicationYear "2015" @default.
• W2109611268 type Work @default.
• W2109611268 sameAs 2109611268 @default.
• W2109611268 citedByCount "123" @default.
• W2109611268 countsByYear W21096112682015 @default.
• W2109611268 countsByYear W21096112682016 @default.
• W2109611268 countsByYear W21096112682017 @default.
• W2109611268 countsByYear W21096112682018 @default.
• W2109611268 countsByYear W21096112682019 @default.
• W2109611268 countsByYear W21096112682020 @default.
• W2109611268 countsByYear W21096112682021 @default.
• W2109611268 countsByYear W21096112682022 @default.
• W2109611268 countsByYear W21096112682023 @default.
• W2109611268 crossrefType "journal-article" @default.
• W2109611268 hasAuthorship W2109611268A5000750846 @default.
• W2109611268 hasAuthorship W2109611268A5003572390 @default.
• W2109611268 hasAuthorship W2109611268A5005591514 @default.
• W2109611268 hasAuthorship W2109611268A5010990164 @default.
• W2109611268 hasAuthorship W2109611268A5012863731 @default.
• W2109611268 hasAuthorship W2109611268A5015140142 @default.
• W2109611268 hasAuthorship W2109611268A5015493242 @default.

• next